SecBot SecBot
Biotech Drug Report Generated Oct 27, 2026

del-desiran

NVS·NOVARTIS AG
BEARISH
Drug Impact Rating3/10
Trial phase
Phase 3 (completed, failed primary endpoint)
Time to market
Unknown, the Phase 3 trial failed its primary endpoint, and no regulatory submission path has been determined. The drug may be years away or may never reach market.
Why 3/10
No upcoming binary catalyst is scheduled, the Phase 3 HARBOR trial has already failed its primary endpoint (September 8, 2026), and Novartis has not committed to a regulatory filing. For a large-cap pharma like NVS (~$200B+ market cap), del-desiran is one of many pipeline assets, so even a complete program termination would be a modest incremental headwind rather than a company-defining event.
Actionable Insight BEARISH

The Phase 3 HARBOR trial has already failed, and no regulatory submission or next pivotal readout is scheduled. Watch for Novartis's full data presentation at a medical conference and any decision on whether to pursue a regulatory path based on secondary endpoints, either outcome would be incremental for a stock with a $200B+ market cap and dozens of marketed products.

Price Chart

Loading chart...

Executive Summary

Del-desiran (delpacibart etedesiran, formerly AOC 1001) is an antibody-oligonucleotide conjugate developed by Novartis (NVS) for myotonic dystrophy type 1 (DM1), a rare progressive muscle-wasting disease with no approved treatments. The drug was the lead asset from Novartis's ~$12B acquisition of Avidity Biosciences. On September 8, 2026, Novartis announced that the global Phase 3 HARBOR trial failed to meet its primary endpoint (video hand opening time), sending NVS shares down ~14% in a single day. While Novartis reported "evidence of clinical activity" in secondary endpoints, the company has not committed to a regulatory path and is still analyzing the full dataset. For a large-cap pharma like Novartis, this is a meaningful pipeline setback but not a company-threatening event.

How It Works

Del-desiran is an antibody-oligonucleotide conjugate, a synthetic molecule that combines a targeting antibody with a short piece of genetic material (siRNA). The antibody portion binds to a receptor (TfR1) found on muscle cells, which pulls the drug inside those cells. Once inside, the siRNA component triggers the cell's natural machinery to degrade the toxic DMPK RNA that causes myotonic dystrophy type 1, aiming to address the root cause of the disease.

Trial Status

The global Phase 3 HARBOR trial (NCT06411288) enrolled 159 patients with DM1 and randomized them to del-desiran or placebo every 8 weeks for 7 doses. The trial completed in July 2026. Topline results announced September 8, 2026 showed the drug did not meet its primary endpoint (video hand opening time, vHOT) with statistical significance. Novartis reported "evidence of clinical activity" in secondary and exploratory endpoints but has not disclosed detailed data. The company is analyzing the full dataset and plans to discuss next steps with health authorities.

The Two-Sided Case

▲ Bull Case3
Novartis reported 'evidence of clinical activity' in secondary endpoints and exploratory analyses, suggesting the drug may have biological effect that could be captured with a different trial design or endpoint
DM1 has zero approved treatments and high unmet need, any therapy showing meaningful benefit could still find a regulatory path
The antibody-oligonucleotide conjugate platform (AOC) could be validated for other indications even if the DM1 program needs redesign
▼ Bear Case4
The Phase 3 HARBOR trial failed its primary endpoint of vHOT with no statistical significance versus placebo, a clear binary failure for the lead asset of the ~$12B Avidity acquisition
Novartis shares dropped ~14% on the news (one of the worst single-day declines in company history), reflecting investor disappointment and lost confidence in the deal thesis
The failure raises questions about the broader AOC platform and Novartis's dealmaking strategy, especially coming on the heels of the pelacarsen Phase 3 miss days earlier
No approved DM1 therapy exists, and this failure resets the timeline for patients and investors to zero

Upcoming Catalysts

  • Full HARBOR dataset presentation at a future medical conference (date TBD)
  • Regulatory discussions with FDA and other health authorities on potential path forward
  • Novartis decision on whether to continue development or terminate the program

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVARTIS AG 6-K NVS ·Originating report

Sources · 8

Hover a chip for the title
1 novartis.com2 statnews.com3 fiercebiotech.com4 clinicaltrials.gov5 nejm.org6 musculardystrophynews.com7 morningstar.com8 msn.com